Manufacturing US puts $125m into personalised RNA therapy production PharmaphorumFederal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines.Read full story pharminent September 2, 2026 (Last updated: September 2, 2026) Pharmaphorum Federal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines. Read full story Post navigation Previous: Takeda and Weave Bio collaborate on AI-driven automation in drug developmentNext: Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology Related Stories Manufacturing Samsung Biologics inks $262M manufacturing deal with European pharma company pharminent September 11, 2026 Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026